- Idera (NASDAQ:IDRA) states clinical safety data for its IMO-8400 B-cell lymphoma drug supports "dose escalation in ongoing Phase 1/2 trials." In addition, preclinical data shows the potential for a combination therapy featuring IMO-8400 and rituximab (a monoclonal antibody).
- If all goes as planned, Idera expects to receive final 24-week safety and clinical activity data for an Phase 1/2 dose escalation trial in 2H15.
- Shares rose 9.2% in regular trading after Idera provided positive preclinical data for its IMO-2055 cancer drug.